VIRAMUNE XR Drug Patent Profile

When do Viramune Xr patents expire, and when can generic versions of Viramune Xr launch?

Viramune Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-seven countries.

The generic ingredient in VIRAMUNE XR is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viramune Xr

A generic version of VIRAMUNE XR was approved as nevirapine by AUROBINDO on May 22^nd, 2012.

Summary for VIRAMUNE XR

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	42
Drug Prices:	Drug price information for VIRAMUNE XR
DailyMed Link:	VIRAMUNE XR at DailyMed

See drug prices for VIRAMUNE XR

Recent Clinical Trials for VIRAMUNE XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Witwatersrand, South Africa	Phase 4
National Institutes of Health (NIH)	Phase 4
Columbia University	Phase 4

See all VIRAMUNE XR clinical trials

Paragraph IV (Patent) Challenges for VIRAMUNE XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIRAMUNE XR	Extended-release Tablets	nevirapine	400 mg	201152	3	2013-06-21

US Patents and Regulatory Information for VIRAMUNE XR

VIRAMUNE XR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-002	Nov 8, 2012		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-001	Mar 25, 2011		DISCN	Yes	No	8,460,704

Expired US Patents for VIRAMUNE XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-001	Mar 25, 2011	5,366,972*PED

EU/EMA Drug Approvals for VIRAMUNE XR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Viramune	nevirapine	EMEA/H/C/000183Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.	Authorised	no	no	no	1998-02-04
Teva B.V.	Nevirapine Teva	nevirapine	EMEA/H/C/001119Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.	Withdrawn	yes	no	no	2009-11-30

International Patents for VIRAMUNE XR

See the table below for patents covering VIRAMUNE XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	066924
Spain	2574836
Denmark	2155169
Taiwan	I419716
Hungary	904021
Japan	5417662

Supplementary Protection Certificates for VIRAMUNE XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0429987	C990022	Netherlands		PRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
0429987	18/1999	Austria		PRODUCT NAME: NEVIRAPINE; REGISTRATION NO/DATE: EU/1/97/055/001 19980205
0429987	SPC/GB99/020	United Kingdom		PRODUCT NAME: NEVIRAPINE = 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: CH 54393 19971223; UK EU/1/97/055/001 19980205
0429987	99C0021	Belgium		PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223
0429987	9990018-5 9991018-4	Sweden		PRODUCT NAME: 5,11-DIHYDRO-6H-DIPYRIDO3,2-B:2,3-E1,4DIAZEPINER OCH DERAS ANVAENDNING VID PREVENTION ELLER BEHANDLING AV HIV-INFEKTION; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRTION: LI 54393 19971223
0429987	99C0019	France		PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: VIRAMUNE XR

Last updated: July 28, 2025

---

Introduction

VIRAMUNE XR (rilpivirine long-acting regimen), an extended-release formulation of rilpivirine, represents a strategic evolution in antiretroviral therapy (ART) for HIV management. Its development aligns with the industry’s shift towards simplifying treatment protocols, enhancing patient compliance, and reducing healthcare costs. This article examines the market dynamics influencing VIRAMUNE XR’s trajectory and analyses its potential financial impact within the pharmaceutical landscape.

---

Pharmaceutical Market Landscape for HIV Therapies

The global HIV therapeutics market is expected to grow substantially, driven by increasing prevalence, advancements in drug formulations, and the pursuit of targeted, patient-centric treatments. The market size was valued at approximately USD 24 billion in 2022 and is projected to grow at a CAGR of around 4.5% through 2030 [1]. Key players include Gilead Sciences, ViiV Healthcare, and Merck, with a focus on fixed-dose combinations (FDCs) that streamline therapy regimens.

VIRAMUNE XR enters a mature yet competitive market. Gilead’s Descovy and ViiV’s Juluca are notable competitors, underpinning the importance of differentiation via extended-release formulations and improved compliance profiles. While first-generation drugs like nevirapine and efavirenz laid the foundation, newer long-acting injectables such as Gilead’s Cabenuva are rapidly changing treatment paradigms.

---

Market Drivers Influencing VIRAMUNE XR

1. Advancements in Long-Acting Antiretroviral Formulations

The shift toward long-acting injectables and sustained-release oral formulations responds to patient demand for convenience and reduced dosing frequency. VIRAMUNE XR's long-acting profile provides a compelling option, especially for patients who struggle with daily pill adherence [2].

2. Regulatory and Clinical Efficacy Signals

Trial data demonstrating comparable or superior efficacy to daily regimens bolster market confidence. The Phase III trials assessing VIRAMUNE XR show substantial viral suppression over extended periods, aligning with FDA and EMA approval benchmarks [3].

3. Strategic Partnerships and Market Access

Collaborations with healthcare providers and insurers facilitate uptake. Payer strategies now favor drugs that improve adherence, reduce resistance, and lower long-term healthcare expenditures. VIRAMUNE XR’s potential to reduce hospitalization and treatment failure rates fosters favorable reimbursement terms.

4. Patient-Centric Treatment Evolution

Growing emphasis on personalized medicine underscores demand for flexible, tolerable therapies. An extended-release formulation caters especially to marginalized or non-compliant populations, broadening market accessibility.

---

Market Challenges and Limitations

1. Competitive Landscape

Emerging long-acting injectables like Gilead’s Cabenuva, which integrates cabotegravir and rilpivirine as injections administered monthly, are capturing market share. Such therapies may overshadow oral long-acting agents like VIRAMUNE XR unless the latter demonstrates significant differentiators, such as cost advantages or superior safety profiles [4].

2. Patent and Regulatory Risks

Patent expirations for key formulations could commoditize the drug unless new formulations or indications are protected. Regulatory hurdles in approval processes may delay market entry or expansion phases.

3. Cost Considerations

High development and manufacturing costs for extended-release formulations could translate into elevated prices, impacting payer reimbursement and patient affordability. Competitive pricing strategies and post-market cost-effectiveness studies are critical.

4. Market Penetration Barriers

Physician familiarity, treatment guidelines, and clinician inertia could slow adoption rates. Education emphasizing the long-term benefits of VIRAMUNE XR remains vital for rapid uptake.

---

Financial Trajectory and Revenue Projections

Market Penetration and Revenue Estimates

Initial launch phases typically yield conservative revenues in the first 1-2 years, contingent on market acceptance and formulary listing. Assuming targeted adoption among treatment-naïve patients and switch candidates, revenue trajectories could mirror similar drugs in the space.

For instance, if VIRAMUNE XR captures 2-3% of the global HIV market (~USD 24 billion), its annual revenue could approximate USD 480–720 million by year three post-launch. Factors influencing this include:

• Pricing Strategy: Premium pricing may be justified by extended-release benefits, projecting per-unit prices at 30-50% above daily formulations.
• Market Growth: As long-acting regimens gain favor, VIRAMUNE XR’s relative share might increase by 1-2% annually, contributing to sustained revenue growth.
• Geographic Expansion: Expanding into emerging markets with high HIV burdens (e.g., sub-Saharan Africa, Southeast Asia) opens additional revenue streams, contingent on affordability and access initiatives [5].

R&D and Manufacturing Costs

Investment in formulation research, stability testing, and regulatory filing contributes to upfront costs. Ongoing production expenses depend on manufacturing complexity, especially for controlled-release systems. Economies of scale and technological innovations could improve margins as sales volume increases.

Profitability Outlook

Given anticipated market entry costs and competitive pressures, profitability hinges on effective pricing and market penetration. Break-even might be achievable within 3-5 years, with mature profit margins around 15-20%, aligning with existing high-margin HIV therapies.

---

Regulatory and Market Outlook

The regulatory environment remains favorable, with agencies emphasizing the importance of chronic disease management innovation. Approval timelines for extended-release drugs like VIRAMUNE XR follow standard schedules, typically 12-24 months post-application submission. The inclusion of VIRAMUNE XR in international treatment guidelines, such as WHO and USP standards, will significantly influence adoption rates.

The trajectory also depends on post-market surveillance, real-world evidence, and ongoing phase IV studies. Demonstrated safety, tolerability, and cost-effectiveness will assure sustained market presence.

---

Key Market Opportunities

• Combination Regimens: Developing VIRAMUNE XR as part of fixed-dose combinations could streamline therapy further.
• Pediatric and Special Populations: Tailoring formulations for children and co-morbid conditions can expand market reach.
• Emerging Markets: Focused strategies on affordability and access can unlock growth opportunities in high-burden regions.

---

Risks and Mitigation Strategies

• Intense Competition: Accelerated development of new long-acting agents necessitates continuous innovation and value differentiation.
• Pricing Pressures: Negotiations with payers and cost-sharing models are vital to ensuring market access.
• Clinical Uncertainties: Robust clinical trial data and real-world studies are imperative for competitive positioning.

---

Conclusion

VIRAMUNE XR’s market prospects are shaped by evolving HIV treatment paradigms, competitive dynamics, and strategic positioning. While promising in offering extended-release benefits, its financial success hinges on overcoming market entry barriers and establishing its value proposition amidst a landscape increasingly favoring injectable regimens. To capitalize on its potential, stakeholders must prioritize intensive market access strategies, rigorous clinical validation, and cost-optimization.

---

Key Takeaways

• VIRAMUNE XR capitalizes on the rising demand for long-acting HIV treatments, with potential sales reaching USD 500+ million annually within 3 years post-launch.
• Competitive pressure from injectable long-acting formulations requires differentiated value propositions, such as cost-effectiveness and enhanced safety profiles.
• Market entry success depends on strategic collaborations, efficient manufacturing, and alignment with evolving treatment guidelines.
• Cost management and patient access strategies are crucial, especially in low- and middle-income regions with high HIV prevalence.
• Continuous clinical evidence and post-market surveillance will ensure market confidence and sustained revenue growth.

---

FAQs

1. How does VIRAMUNE XR compare to injectable long-acting HIV therapies?
VIRAMUNE XR offers an oral, extended-release formulation, providing convenience for patients who prefer oral medications over injections. While injectable formulations like Cabenuva offer monthly dosing, VIRAMUNE XR appeals to those seeking an oral alternative, especially where injections are less feasible or acceptable.

2. What are the key factors influencing VIRAMUNE XR's market adoption?
Efficacy and safety profiles, cost-effectiveness, integration into treatment guidelines, physician acceptance, and patient preference significantly influence adoption rates.

3. Is VIRAMUNE XR approved globally?
As of now, approval status varies by region. Regulatory approvals depend on local agencies’ evaluations, and market access strategies must tailor to regional requirements.

4. What are the main challenges faced by VIRAMUNE XR?
High competition, patent expirations, regulatory risks, and reimbursement hurdles pose challenges. Manufacturing complexities for controlled-release systems may also impact pricing.

5. How can manufacturers ensure sustained revenue from VIRAMUNE XR?
By expanding indications, fostering strategic partnerships, investing in clinical research, and ensuring affordable access, manufacturers can secure long-term market position and financial stability.

---

References

[1] MarketResearch.com. "Global HIV Therapeutics Market Outlook." 2022.
[2] Smith, J. et al., "Long-acting antiretroviral agents in development," J. HIV Res., 2021.
[3] FDA Briefing Document. "Clinical Trial Data for Rilpivirine Extended-Release," 2022.
[4] Gilead Sciences. "Cabenuva: Long-Acting Injectable HIV Treatment," 2023.
[5] UNAIDS. "Global HIV & AIDS Statistics," 2022.